From the top 20 differentially expressed genes and the activated keratinization proliferation and epidermis development biological processes in recurrent ESCC, we identified TP63 as a putative biomarker to predict the clinical outcome. This evidence concerns the gene TP63 and esophageal squamous cell carcinoma.